CAR T cell immunotherapy for human cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 29567707.
- Also identified by DOI 10.1126/science.aar6711.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Adoptive T cell transfer (ACT) is a new area of transfusion medicine involving the infusion of lymphocytes to mediate antitumor, antiviral, or anti-inflammatory effects. The field has rapidly advanced from a promising form of immuno-oncology in preclinical models to the recent commercial approvals of chimeric antigen receptor (CAR) T cells to treat leukemia and lymphoma. This Review describes opportunities and challenges for entering mainstream oncology that presently face the CAR T field, with a focus on the challenges that have emerged over the past several years.
Medical subject headings
- Cell Engineering
- Immunotherapy, Adoptive
- Mutant Chimeric Proteins
- Neoplasms
- Receptors, Antigen, T-Cell
- T-Lymphocytes